Screener
Madrigal Pharmaceuticals, Inc. MDGL Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(152,330) | $(115,519) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 69,389 | 46,090 |
| Depreciation and amortization expense | 767 | 756 |
| Inventory write-down | 11,051 | — |
| Amortization of debt issuance costs and discount | 913 | 807 |
| Amortization of right-of-use assets | 1,053 | 111 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s stock-based comp?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported stock-based comp of $35.37M in Q2 2026.
- How has Madrigal Pharmaceuticals, Inc.'s stock-based comp changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s stock-based comp increased by 40.6% year-over-year, from $25.16M to $35.37M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s stock-based comp has grown at a 38.2% compound annual growth rate (CAGR), from $26.87M to $98.13M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude